One of the more prominent developments to our proposition of late has been the focus towards renewables and in particular, green tech.

Companies at the coalface of the renewables revolution, who in recent months have shot from a nice-to-have to a near essential allocation.

I spoke with James Sullivan on this very subject earlier in the week:

“Over the past weeks, it’s fair to say that life as we know it has changed. When observing the current landscape, it’s clear that the COVID-19 pandemic has left few stones unturned with regards to our day to day living.”

He continued “The government’s lockdown measures have presented the most brutal of litmus tests for businesses across the world.”

Indeed for many companies, the rigidity of circumstance may prove altogether too much to overcome. But for others whom are, either through industry, resource or sheer good luck, able to be flexible, there is hope.

Within the technology sector, we are witnessing this dispersion in real time.

James, echoing the sentiments of our 2018 note ‘Seeking closure on the ‘Growth vs Value’ debate‘, surmised that “companies that are nimble and able to adapt their output to meet society’s current needs will rise to the top. Those that cannot will be left behind.”

Thermo Fisher Scientific, to whom we have exposure via our SRI model portfolios, made headlines earlier in the month after agreeing to supply Coronavirus testing kits to the UK, as part of the government’s bid to increase daily testing.

The US-based scientific equipment maker has been fleet-footed in gearing its production towards pandemic related solutions. Its timely acquisition of diagnostics group Qiagen at the beginning of March, a move that had long been mooted, being a notable case in point.

Qiagen, having previously produced testing apparatus for both SARS and Swine Flu, had been developing COVID-19 testing kits since the turn of the year. The $11.5bn deal facilitates an expansion in Thermo’s disease testing arm at a time when it is most needed.

In addition, the company has partnered with Ford in a bid to hasten development of the COVID-19 collection kits, specifically the vials used for ‘drive-through’ testing. Ford engineers are assisting Thermo in adapting their production machinery to meet the increased demand, whilst facilitating other solutions such as reusable medical gowns made from airbag material.

This type of evolutionary innovation is of course nothing new, one need only read up on the origins of the cordless drill (a joint venture between Black & Decker and NASA) for proof of this.  But from an investment perspective, a company’s willingness to evolve and be alive to its surroundings, has never felt more pertinent.

In a post-pandemic society, we believe our fascination with, and indeed reliance on, technology will accelerate ten-fold.

Within the multi asset funds, we have opened several positions within this space, leveraging off the MPS team’s experience in ‘responsible’ investing.

James concluded that “having been at the forefront of the largest bull-run in history, we suspect that technology will rise again and the companies seeking to aid the world’s problems – climate change, water scarcity and in this case, infection – will surely stand to benefit.”



MitonOptimal UK Limited
Royal Mead
Railway Place


t: +44 (0) 1225 632 250
f: +44 (0) 1225 439 442

Regulatory Information

Regulatory Information
MitonOptimal UK is a trading name of AB Investment Solutions Limited. AB Investment Solutions is a subsidiary of Alpha Beta Partners Limited.  Registered in England and Wales No. 09138865.  Authorised and regulated by the Financial Conduct Authority.

Send this to a friend

Terms & Conditions


By using or accessing any part of our website, aside from the Terms and Conditions page, you agree to be legally bound by those terms and conditions. We may amend these terms and conditions at any time without notice. Your continued use of our website following any change will constitute your acceptance of such change. Our full terms and conditions can be found at

Regulatory Information

The MitonOptimal Group (“MitonOptimal”) of companies is authorised and regulated in their respective jurisdictions, as required by law. For further details, you may visit the regional sites via

MitonOptimal UK Limited is part of the MitonOptimal group of companies. MitonOptimal UK Limited is registered in England and Wales No. 09138865. Authorised and regulated by the Financial Conduct Authority.

Risk Warning

Potential investors should be aware that our models and funds may make investments in equities, bonds, cash, commodities alternative strategies and commercial property. Investors should be aware that there is no guarantee that investments will go up.  Past performance is no guide as to future performance. As the price of units and the amount of income distributed or accumulated may go down as well as up, the Manager has no obligation to redeem units at the subscription price originally paid. If you are in any doubt about the content of these terms and conditions, you should not enter the site and consult your stockbroker, bank manager, solicitor, accountant or professional investment advisors.

If you have any questions or concerns about our website please email us at [email protected].

Please indicate below, whether you accept/do not accept our terms and conditions of use.